These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 11198371)

  • 1. A novel chemotherapeutic combination for Trichomonas vaginalis targeting purine salvage pathways of the parasite.
    Afifi MA; el-Wakil HS; Abdel-Ghaffar MM
    J Egypt Soc Parasitol; 2000 Dec; 30(3):735-46. PubMed ID: 11198371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the iron chelator deferoxamine on Trichomonas vaginalis in vitro.
    Mahmoud MS
    J Egypt Soc Parasitol; 2002 Dec; 32(3):691-704. PubMed ID: 12512803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine is the primary precursor of all purine nucleotides in Trichomonas vaginalis.
    Munagala NR; Wang CC
    Mol Biochem Parasitol; 2003 Apr; 127(2):143-9. PubMed ID: 12672523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HeLa cell nucleus, a source of thymidine for Trichomonas vaginalis growing in vitro.
    González-Lázaro M; González-Robles A; Hernández-Gutiérrez R; Arroyo R
    Int J Biochem Cell Biol; 2005 Jan; 37(1):166-76. PubMed ID: 15381159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive characterization of purine and pyrimidine transport activities in Trichomonas vaginalis and functional cloning of a trichomonad nucleoside transporter.
    Natto MJ; Miyamoto Y; Munday JC; AlSiari TA; Al-Salabi MI; Quashie NB; Eze AA; Eckmann L; De Koning HP
    Mol Microbiol; 2021 Dec; 116(6):1489-1511. PubMed ID: 34738285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of inhibitors of purine metabolism on two trichomonad species.
    Wang CC; Verham R; Cheng HW; Rice A; Wang AL
    Biochem Pharmacol; 1984 Apr; 33(8):1323-9. PubMed ID: 6608946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility of Trichomonas vaginalis to AT-specific minor groove binding drugs.
    Chavalitshewinkoon-Petmitr P; Ramdja M; Kajorndechakiat S; Ralph RK; Denny WA; Wilairat P
    J Antimicrob Chemother; 2003 Aug; 52(2):287-9. PubMed ID: 12837730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis.
    Dunne RL; Dunn LA; Upcroft P; O'Donoghue PJ; Upcroft JA
    Cell Res; 2003 Aug; 13(4):239-49. PubMed ID: 12974614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of fibronectin by Trichomonas vaginalis is influenced by iron and calcium.
    Crouch ML; Benchimol M; Alderete JF
    Microb Pathog; 2001 Sep; 31(3):131-44. PubMed ID: 11500098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purine salvage enzymes in Trichomonas vaginalis.
    Miller RL; Miller WH
    Adv Exp Med Biol; 1986; 195 Pt B():573-5. PubMed ID: 3020926
    [No Abstract]   [Full Text] [Related]  

  • 11. Polyamine Transport and Synthesis in Trichomonas vaginalis: Potential Therapeutic Targets.
    Alvarez-Sanchez ME; Villalpando JL; Quintas-Granados LI; Arroyo R
    Curr Pharm Des; 2017; 23(23):3359-3366. PubMed ID: 28671057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of tritiated hypoxanthine, adenine and adenosine for purine-salvage incorporation into nucleic acids of the malarial parasite, Plasmodium berghei.
    Van Dyke K
    Tropenmed Parasitol; 1975 Jun; 26(2):232-8. PubMed ID: 1099747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic.
    Schmid G; Narcisi E; Mosure D; Secor WE; Higgins J; Moreno H
    J Reprod Med; 2001 Jun; 46(6):545-9. PubMed ID: 11441678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of iron on the virulence of Trichomonas vaginalis.
    Ryu JS; Choi HK; Min DY; Ha SE; Ahn MH
    J Parasitol; 2001 Apr; 87(2):457-60. PubMed ID: 11318588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of metronidazole-resistant Trichomonas vaginalis--a new approach.
    Mammen-Tobin A; Wilson JD
    Int J STD AIDS; 2005 Jul; 16(7):488-90. PubMed ID: 16004628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative drugs against Trichomonas vaginalis.
    Mahdi NK; Gany ZH; Sharief M
    East Mediterr Health J; 2006 Sep; 12(5):679-84. PubMed ID: 17333809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The chitinase system from Trichomonas vaginalis as a potential target for antimicrobial therapy of urogenital trichomoniasis.
    Loiseau PM; Bories C; Sanon A
    Biomed Pharmacother; 2002 Dec; 56(10):503-10. PubMed ID: 12504272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population.
    Krashin JW; Koumans EH; Bradshaw-Sydnor AC; Braxton JR; Evan Secor W; Sawyer MK; Markowitz LE
    Sex Transm Dis; 2010 Jul; 37(7):440-4. PubMed ID: 20351623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of two cultural media (CPLM & TYM) for isolation and maintenance of Trichomonas vaginalis stocks in the laboratory.
    Abd el Ghaffar FM; Azab ME; Salem SA; Habib KS; Maklad KM; Habib FS
    J Egypt Soc Parasitol; 1994 Dec; 24(3):611-9. PubMed ID: 7844426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptomatic Trichomonas vaginalis infection in the setting of severe nitroimidazole allergy: successful treatment with boric acid.
    Muzny C; Barnes A; Mena L
    Sex Health; 2012 Sep; 9(4):389-91. PubMed ID: 22877600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.